9th Annual Meeting & SCIENTIFIC SESSIONS
Hotel Registration is now open!
To register for a hotel room:
Call the Westin BWI Hotel at 1-866-225-0511 and say that you are attending the INTERMACS 9th Annual Meeting.
(Hotel rooms available for May 14 - 16, 2015)
To register for the Annual Meeting and Scientific Sessions:
Early Registration - Closed
General Registration ($175 plus processing fee) begins February 1, 2015.
Annual Meeting Agenda
Click the link below to register on EventBrite.com
May 15 – 16, 2015
Social, Coordinator’s Meeting, and Annual Meeting
The Westin Baltimore Washington Airport - BWI
1110 Old Elkridge Landing Road
Linthicum Heights, Maryland 21090
Please update your Apple IOS version of Duo Security from your current version to version 3.5.1. The update is available on the Apple iTunes store (Link Below)
This update will fix the protection of the Duo Mobile Security application
The Interagency Registry for Mechanically Assisted Circulatory Support is a North American registry established in 2005 for patients who are receiving mechanical circulatory support device therapy to treat advanced heart failure. Intermacs was established as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Food and Drug Administration (FDA), clinicians, scientists and industry representatives in conjunction with Dr. James K. Kirklin and the University of Alabama at Birmingham.
Intermacs is a prospective registry that collects clinical data, including follow up, essentially as it happens. Post implant follow up data is collected at 1 week, 1 month, 3 months, 6 months and every 6 months thereafter. Major outcomes after implant, e.g. death, explant, rehospitalization and adverse events, are entered as they occur and also as part of the defined follow-up scheduled intervals.
Intermacs provides contemporary data to demonstrate the continued progress of outcomes, with additional insight into appropriate risk stratification and patient selection. Death, transplant, and explant are the major discrete endpoints recorded.
Complex endpoints that include the patient’s level of function and quality of life, critical to the evaluation of current MCSD therapy, for which improvements in both survival and function have been compelling. These indices are becoming increasingly important as the survival improves, and new devices will be compared for outcomes beyond survival.
Sponsored by The National Heart, Lung and Blood Institute (NHLI) and housed at the University of Alabama at Birmingham, Intermacs launched June 2006 with 15 participating hospitals within the United States. The registry has quickly grown to include the majority of VAD centers in the U.S, is recognized as the Joint Commission mandated registry for all U.S. centers implanting VADS for destination therapy and now has expanded to include all interested hospitals in the United States and Canada.
Intermacs is sensitive to site and participant confidentiality. Please use a secure e-mail to communicate confidential information with Intermacs staff. If you do not have a secure e-mail available, contact us at firstname.lastname@example.org and request access to the Intermacs secure e-mail.
This project has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract Number HHSN268201100025C.